Display options
Share it on
Full text links
Atypon Free PMC Article

Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):589-93. doi: 10.1073/pnas.91.2.589.

Functional analysis of myosin missense mutations in familial hypertrophic cardiomyopathy.

Proceedings of the National Academy of Sciences of the United States of America

A J Straceski, A Geisterfer-Lowrance, C E Seidman, J G Seidman, L A Leinwand

Affiliations

  1. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461.

PMID: 8290568 PMCID: PMC42994 DOI: 10.1073/pnas.91.2.589
Free PMC Article

Abstract

To analyze potential functional consequences of myosin heavy chain (MHC) mutations identified in patients with familial hypertrophic cardiomyopathy (FHC), we have assessed the stability of the mutant MHCs and their ability to form thick filaments. Constructs encoding wild-type rat alpha MHC and seven corresponding FHC missense mutants were transfected into COS cells. Immunoblot analysis suggested that FHC mutations do not grossly alter protein stability. Wild-type alpha MHC transfected into COS cells forms structures previously shown to be arrays of thick filaments, which also resemble myosin structures observed early in differentiation of muscle cells. Surprisingly, up to 29% of COS cells transfected with the FHC mutants failed to form filamentous structures. To assess whether this phenotype was specific for the FHC mutants and not generalizable to any myosin mutation, COS cells were transfected with a construct encoding an MHC with a 168-amino acid deletion of the hinge/rod region. This deletion construct formed filamentous structures with the same frequency as wild-type MHC. Biochemical analysis of one FHC mutant (Arg-249-->Gln) demonstrates that the structures formed by the mutant are solubilized at a lower ionic strength than those formed by wild-type MHC. We conclude that although the FHC mutant MHC is not labile, its assembly properties may be impaired.

Cited by

References

  1. Biochemistry. 1988 Sep 6;27(18):6977-82 - PubMed
  2. Annu Rev Biophys Biophys Chem. 1988;17:217-39 - PubMed
  3. Genes Dev. 1989 Feb;3(2):131-40 - PubMed
  4. Cardiol Clin. 1988 May;6(2):233-88 - PubMed
  5. Circulation. 1989 Nov;80(5):1489-92 - PubMed
  6. J Mol Biol. 1989 Dec 5;210(3):665-71 - PubMed
  7. Cell. 1990 Sep 7;62(5):991-8 - PubMed
  8. Cell. 1990 Sep 7;62(5):999-1006 - PubMed
  9. J Virol. 1991 Aug;65(8):4292-300 - PubMed
  10. J Cell Biol. 1991 Aug;114(4):725-33 - PubMed
  11. N Engl J Med. 1992 Apr 23;326(17):1108-14 - PubMed
  12. Circ Res. 1992 Dec;71(6):1404-9 - PubMed
  13. Cell Motil Cytoskeleton. 1993;26(3):192-204 - PubMed
  14. J Mol Biol. 1974 Dec 5;90(2):291-300 - PubMed
  15. J Mol Biol. 1977 Jul;114(1):133-40 - PubMed
  16. Am J Cardiol. 1978 Jun;41(7):1133-40 - PubMed
  17. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 - PubMed
  18. Circulation. 1982 Jun;65(7):1388-94 - PubMed
  19. Methods Enzymol. 1982;85 Pt B:55-71 - PubMed
  20. J Mol Biol. 1985 Jun 25;183(4):543-51 - PubMed
  21. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1393-7 - PubMed
  22. Nucleic Acids Res. 1987 Jul 10;15(13):5443-59 - PubMed
  23. J Biol Chem. 1989 Aug 5;264(22):13122-30 - PubMed

Substances

MeSH terms

Publication Types

Grant support

LinkOut - more resources